G6P-40790-46915
4 vaccinations
2 coded responses
49 check-ins
2 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 908 / CA
- Registered
- 2020-12-21
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Registered dependents
QNN-16804-80967
Child or adolescent in my care · Male · 2022-07-09
JU2-13059-22207
Child or adolescent in my care · Male · 2022-07-09
VD4-32214-83123
Child or adolescent in my care · Male · 2022-07-09
Timeline
-
2020-12-21
Registered in v-safe
-
2020-12-21
Dose 1 — Pfizer-BioNTech
- 2020-12-21
- 2020-12-22
- 2020-12-23
- 2020-12-24
- 2020-12-25
- 2020-12-26
- 2020-12-27
- 2020-12-28
- 2021-01-04
-
2021-01-11
Dose 2 — Pfizer-BioNTech
- 2021-01-11
- 2021-01-12
- 2021-01-13
- 2021-01-14
- 2021-01-15
- 2021-01-16
- 2021-01-17
- 2021-01-18
-
2021-01-25
Survey response — 14 day, dose 2MedDRA: Endometritis decidual, Hospitalisation — Feeling: Good · Get care from a doctor or other healthcare professional · Emergency room or emergency department visitMedDRA releases: 2021-09,2023-04,2024-11 · check-in answers available
-
2021-01-25
Report sent to call center — 14 day, dose 2Get care from a doctor or other healthcare professional1 call case(s)
-
2021-02-01
Survey response — 21 day, dose 2MedDRA: Postpartum haemorrhage, Retained products of conception, Uterine dilation and curettage — Feeling: Good · Get care from a doctor or other healthcare professional · Emergency room or emergency department visitMedDRA releases: 2021-09,2023-04,2024-11 · check-in answers available
-
2021-02-01
Report sent to call center — 21 day, dose 2Get care from a doctor or other healthcare professional1 call case(s)
- 2021-02-10
- 2021-02-15
- 2021-02-22
- 2021-03-02
-
2021-03-02
Call successfulNot applicable (accidental reporting or does not believe symptoms are related to vaccine)
- 2021-04-12
- 2021-07-13
-
2021-09-29
Dose 3 — Pfizer-BioNTech
- 2021-09-29
- 2021-09-30
- 2021-10-01
- 2021-10-02
- 2021-10-03
- 2021-10-04
- 2021-10-05
- 2021-10-06
- 2021-10-15
- 2021-10-20
- 2021-10-27
- 2021-11-03
- 2021-11-10
- 2021-12-29
- 2022-03-30
-
2022-09-10
Dose 4 — ModernaCo-administered: Flu
- 2022-09-14
- 2022-09-16
- 2022-09-17
- 2022-09-24
- 2022-10-03
- 2022-10-10
- 2022-10-17
- 2022-10-22
- 2022-12-10
- 2023-03-11
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-21 | Pfizer-BioNTech | |
| 2 | 2021-01-11 | Pfizer-BioNTech | |
| 3 | 2021-09-29 | Pfizer-BioNTech | No |
| 4 | 2022-09-10 | Moderna | Flu |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2021-01-25 | Successful | Not applicable (accidental reporting or does not believe symptoms are related to vaccine) |
| 2021-02-01 | Successful 2021-03-02 |
Not applicable (accidental reporting or does not believe symptoms are related to vaccine) |
Free text
Release 2
Symptoms: Admission to hospital for postpartum endometritis.
Release 3
Symptoms: Late Postpartum hemorrhage for retained products which required D&C
Free-text releases are not linked to a specific survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Endometritis decidual | ✓ | ✓ | ✓ |
| SD | Hospitalisation | ✓ | ✓ | ✓ |
| SD | Postpartum haemorrhage | ✓ | ✓ | ✓ |
| SD | Retained products of conception | ✓ | ✓ | ✓ |
| SD | Uterine dilation and curettage | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release